Article Text

Download PDFPDF
Raloxifene reduced vertebral fractures in postmenopausal women

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

 QUESTION: In postmenopausal women with osteoporosis, does raloxifene reduce the rate of vertebral and non-vertebral fractures?


Randomised (allocation concealed*), blinded (patients, clinicians, and outcome assessors),* placebo controlled trial.


180 clinical centres in 25 countries.


7705 postmenopausal women (mean age 67 y, 96% white) with osteoporosis. Exclusion criteria included other bone diseases, postmenopausal symptoms, abnormal uterine bleeding, history of breast or endometrial cancer or thromboembolic disorders, other cancers, treated endocrine disorders except type 2 diabetes or hypothyroidism, renal lithiasis, abnormal hepatic or renal function, untreated malabsorption, and consumption of >4 drinks of alcohol/d. Follow up was 89%.


Women received calcium, 500 mg/d, and cholecalciferol, 400 to 600 IU/d, and were allocated …

View Full Text


  • Source of funding: Eli Lilly and Company.

  • For correspondence: Dr B Ettinger, Division of Research, Kaiser Permanente Medical Care Program, 3505 Broadway, 13th Floor, Oakland, CA 94611-5400, USA. Fax +1 510 450 2097.

  • * See glossary.